Edina von Rottenthaler, MD
Internal Medicine · Pell City, ALNPI 1770632341
Payments from drug & device makers
Across 255 payments — averaging $16.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Collegium Pharmaceutical, Inc.$762
- Boston Scientific$541
- AbbVie$425
- Biodelivery Sciences International, Inc.$354
- Medtronic$239
- Scilex Pharmaceuticals Inc.$230
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,29999%
- Education$271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 58 | $762 |
| Boston Scientific | 29 | $541 |
| AbbVie(2 entities) | 24 | $425 |
| Biodelivery Sciences International, Inc. | 33 | $354 |
| Medtronic(2 entities) | 7 | $239 |
| Scilex Pharmaceuticals Inc. | 15 | $230 |
| Hikma Pharmaceuticals USA | 14 | $205 |
| Daiichi Sankyo Inc. | 7 | $202 |
| Arbor Pharmaceuticals, Inc. | 7 | $163 |
| Abbott | 9 | $156 |
| Foundation Fusion Solutions, LLC | 1 | $152 |
| Assertio Therapeutics, Inc. | 10 | $113 |
| Indivior Inc. | 4 | $91 |
| Pfizer | 5 | $90 |
| Zyla Life Sciences, Inc. | 6 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $80 |
| Almatica Pharma LLC | 5 | $77 |
| Forte Bio-pharma LLC | 1 | $67 |
| Novartis | 1 | $64 |
| Amgen | 3 | $39 |
| Orexo US, Inc. | 2 | $29 |
| Si-bone, Inc. | 2 | $26 |
| Atland Pharmaceuticals, LLC | 1 | $26 |
| Sentynl Therapeutics, Inc. | 2 | $25 |
| Vertex | 1 | $21 |
| Virtus Pharmaceuticals LLC | 1 | $20 |
| IBSA Pharma Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Vertical Pharmaceuticals, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Morphabond ER$135
- INTELLIS$132
How this compares
$4,326 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelbucaBuprenorphine Hcl | 129 | $96,763 |
| ZtlidoLidocaine | 92 | $81,134 |
| Xtampza ErOxycodone Myristate | 127 | $66,220 |
| Nurtec OdtRimegepant Sulfate | 40 | $61,043 |
| Buprenorphine | 280 | $56,390 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,698 | $37,783 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,316 | $27,447 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 174 | $24,983 |
| SymproicNaldemedine Tosylate | 42 | $18,616 |
| RexultiBrexpiprazole | 13 | $16,632 |
| BotoxOnabotulinumtoxina | 12 | $16,099 |
| Aimovig AutoinjectorErenumab-Aooe | 22 | $16,023 |
| Diclofenac Sodium | 636 | $15,069 |
| LinzessLinaclotide | 26 | $13,903 |
| MovantikNaloxegol Oxalate | 31 | $12,643 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $762 | $162,984256 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone | $205 | $81,373454 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $230 | $81,13492 claims |
| PfizerNurtec Odt | $90 | $61,04340 claims |
| AbbVieBotox, Linzess | $425 | $30,00138 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Pell City
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.